Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, Immunotherapy
21:45 EDT 10 Aug 2012 | Drugs.com
LOS ANGELES--(BUSINESS WIRE)--Aug 8, 2012 - ImmunoCellular Therapeutics (NYSE MKT: IMUC) announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the...
Original Article: Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, Immunotherapy
More From BioPortfolio on "Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, Immunotherapy"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
